MLN0905 is primarily utilized in the field of cancer research and therapy development. It functions as a selective inhibitor of PLK1 (Polo-like kinase 1), a protein kinase that plays a critical role in cell division and mitosis. By inhibiting PLK1, MLN0905 disrupts the proliferation of cancer cells, making it a potential candidate for treating various types of cancers, particularly those characterized by uncontrolled cell growth. Its application is significant in preclinical studies and clinical trials aimed at evaluating its efficacy and safety in targeting tumors. Researchers also explore its potential in combination therapies to enhance the effectiveness of existing cancer treatments.